Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.09% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
201
ArcelorMittal
MT
$55.6B
| $120M | 0.1% |
11,156,719
+3,686,985
| +49% | +$37.2M |
|
202
Innoviva
INVA
$1.5B
| $119M | 0.1% |
8,530,811
+326,800
| +4% | +$4.45M |
|
203
Aecom
ACM
$8.62B
| $119M | 0.1% |
3,165,115
-1,337,900
| -30% | -$47.9M |
|
204
NovoCure
NVCR
$2.06B
| $119M | 0.1% |
2,000,570
-244,900
| -11% | -$16.1M |
|
205
Royal Gold
RGLD
$19.8B
| $118M | 0.1% |
950,842
+285,534
| +43% | +$34.5M |
|
206
Enphase Energy
ENPH
$5.59B
| $116M | 0.1% |
2,435,961
+95,176
| +4% | +$4.55M |
|
207
Universal Display
OLED
$4.32B
| $116M | 0.1% |
772,639
+110,000
| +17% | +$16.1M |
|
|
JNPR
208
DELISTED
Juniper Networks
JNPR
| $115M | 0.1% |
5,026,692
+1,225,600
| +32% | +$28.2M |
|
209
Gentex
GNTX
$5.04B
| $114M | 0.1% |
4,442,235
+238,300
| +6% | +$5.97M |
|
|
ACIA
210
DELISTED
Acacia Communications Inc
ACIA
| $113M | 0.1% |
1,687,659
+1,253,900
| +289% | +$85M |
|
211
C.H. Robinson
CHRW
$17B
| $113M | 0.1% |
1,430,913
+1,197,220
| +512% | +$90.4M |
|
|
FISV
212
Fiserv Inc
FISV
$28B
| $113M | 0.1% |
+1,156,427
| New | +$116M |
|
213
Flowers Foods
FLO
$1.52B
| $113M | 0.1% |
5,031,972
+285,300
| +6% | +$6.43M |
|
|
ECHO
214
EchoStar
ECHO
$25.6B
| $110M | 0.1% |
3,936,801
+233,400
| +6% | +$7.09M |
|
|
XYZ
215
Block Inc
XYZ
$47.5B
| $110M | 0.09% |
1,045,200
+526,200
| +101% | +$40.3M |
|
|
AMTD
216
DELISTED
TD Ameritrade Holding Corp
AMTD
| $109M | 0.09% |
3,006,528
-2,760,792
| -48% | -$104M |
|
217
AB InBev
BUD
$159B
| $109M | 0.09% |
2,210,176
-417,800
| -16% | -$19.5M |
|
218
Telkom Indonesia
TLK
$14.4B
| $109M | 0.09% |
4,975,914
+179,700
| +4% | +$3.8M |
|
219
Berkshire Hathaway Class A
BRK.A
$1.11T
| $109M | 0.09% |
406
+328
| +421% | +$89.9M |
|
220
Commault Systems
CVLT
$5.78B
| $108M | 0.09% |
2,788,887
+558,200
| +25% | +$22.1M |
|
221
Marriott International
MAR
$91.1B
| $108M | 0.09% |
1,258,016
+1,115,800
| +785% | +$96.9M |
|
222
TripAdvisor
TRIP
$1.28B
| $108M | 0.09% |
5,671,384
+1,566,500
| +38% | +$29.9M |
|
223
Morningstar
MORN
$7.33B
| $107M | 0.09% |
759,470
+41,900
| +6% | +$5.92M |
|
224
UDR
UDR
$12B
| $107M | 0.09% |
2,863,416
-1,396,090
| -33% | -$52.1M |
|
225
BCE
BCE
$21.8B
| $107M | 0.09% |
2,556,889
-11,900
| -0.5% | -$490K |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.